2076975 2077203
최종편집 2024-05-19 04:23 (일)
Biktarvy surpasses 10 billion won in 1Q while Dovato enters 2 billion won in sales
상태바
Biktarvy surpasses 10 billion won in 1Q while Dovato enters 2 billion won in sales
  • Hyeokgi Lee, Newsmp
  • 승인 2021.06.16 16:03
  • 댓글 0
이 기사를 공유합니다

Triumeq 79 billion won → 58 billion won, Genvoya 52 billion won → 36 billion won

The focus of the HIV treatment market is shifting to the new generation, which has an advantage in long-term safety.

While the sales of Biktarvy (Gilead Sciences), which relieved the burden of boosters, exceeded 10 billion won in the first quarter, Dovato (GSK), a combination drug, also entered 2 billion mark.

According to IQVIA, Biktarvy recorded sales of 10.5 billion won in 1Q, up 4 billion won YoY.

Biktarvy is dominating the HIV treatment market by widening the gap with Triumeq (GSK), which was one step ahead with 7.9 billion won in 1Q of last year.

With the growth of Biktarvy, sales of Genvoya (Gilead Sciences), the previous generation, fell by 1.6 billion won from 5.2 billion won to 3.6 billion won, and Descovy (Gilead Sciences) also dropped from 1.3 billion won to 1 billion won.

Furthermore, Truvada (Gilead Sciences)’s sales have decreased to 300 million won.

Gilead’s HIV pipeline, where various generations and combinations were mixed, is narrowing down to one treatment, Biktarvy.

For GSK, Dovato expanded its sales to 2.4 billion won, but Triumeq lost its sales from 7.9 billion won to 5.8 billion won. 

Moreover, Tivicay’s 1Q sales were reduced by nearly 300 million won YoY, falling below 1 billion won mark.

The weight on the Triumeq has not yet been fully transferred to Dovato, but the central axis is moving gradually. 

Among other HIV treatments, only Isentress HD (MSD) showed significant growth. It rose 200 million won YoY from 400 million won to 600 million won.

Meanwhile, Kaletra (Abbvie), which received attention due to its potential as an early treatment for COVID-19, saw its sales shrink to 300 million won from 900 million won. 
 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.